Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma

[1]  A. López-Guillermo,et al.  The clinical significance of molecular response in indolent follicular lymphomas. , 1998, Blood.

[2]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[3]  E. Gilboa,et al.  Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA , 1998, Nature Biotechnology.

[4]  J. Fagerberg,et al.  Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. , 1998, Blood.

[5]  T. Kipps,et al.  Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. , 1998, The Journal of clinical investigation.

[6]  H. Rammensee,et al.  Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. , 1998, Cancer research.

[7]  F. Brasseur,et al.  A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma , 1997, The Journal of experimental medicine.

[8]  J. Gribben,et al.  Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. , 1997, Blood.

[9]  D. Czerwinski,et al.  Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. , 1997, Blood.

[10]  J. Schlom,et al.  In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. , 1997, Journal of the National Cancer Institute.

[11]  L. Kwak,et al.  Development of vaccine strategies for the treatment of B-cell malignancies. , 1997, Cancer investigation.

[12]  H. Young,et al.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Krensky,et al.  Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. , 1996, Blood.

[14]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[15]  J. Gribben,et al.  Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Duffey,et al.  Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor , 1995, The Lancet.

[17]  S. Beissert,et al.  Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? , 1995, Immunology today.

[18]  J. Sklar,et al.  Gamma delta T cell recognition of tumor Ig peptide. , 1995, Journal of immunology.

[19]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Levy,et al.  Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.

[21]  N. Arnheim,et al.  Using the polymerase chain reaction to estimate mutation frequencies and rates in human cells. , 1992, Mutation research.

[22]  J. Gribben,et al.  All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. , 1991, Blood.

[23]  P. Greenberg.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.

[24]  E J Freireich,et al.  Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. , 1987, Science.

[25]  S. Rosenberg,et al.  Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. , 1987, Journal of immunology.

[26]  R. Warnke,et al.  Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. , 1985, The New England journal of medicine.

[27]  M. Raffeld,et al.  Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by anti-idiotype. , 1985, The New England journal of medicine.

[28]  R. Fisher,et al.  Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. , 1983, Annals of internal medicine.

[29]  D. Taramelli,et al.  Measurement of macrophage-mediated cytotoxicity against adherent and non-adherent target cells by release of 11 indium-oxine. , 1981, Journal of immunological methods.

[30]  F. Stevenson,et al.  Antibody to a molecularly-defined antigen confined to a tumour cell surface , 1975, Nature.

[31]  H. Eisen,et al.  Myeloma proteins as tumor-specific transplantation antigens. , 1972, Proceedings of the National Academy of Sciences of the United States of America.